Research
Hormonal
Saxagliptin (a DPP-4 inhibitor) is associated with an increased signal of hospitalizations for heart failure (HF), warranting vigilance in high-risk patients.
If you have type 2 diabetes and are at high risk for heart failure, discuss saxagliptin with your doctor. This specific drug has been linked to more hospitalizations for heart failure in some studies, so other options might be safer for your heart.
ModerateRefutesMEDIUM confidence
A signal of increased hospitalisations for HF was observed with saxagliptin, warranting continued evaluation and vigilance in high-risk patients.
Why this rating
Described as a 'signal' requiring 'continued evaluation', implying less definitive causal proof than weight loss.
Source
Implications of incretin-based therapies on cardiovascular disease
Melissa E. Rotz et al. · International Journal of Clinical Practice · 2014
DOI 10.1111/ijcp.12572
systematic_reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists produce significant weight loss (average 1.5–3 kg) in patients with type 2 diabetes, whereas DPP-4 inhibitors have a neutral effect on body weight.Good
- GLP-1 receptor agonists reduce systolic blood pressure by 2–5 mmHg and diastolic blood pressure by 1–3 mmHg, with effects more pronounced than DPP-4 inhibitors.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →